Sign in Subscribe
AIDS (Disease)

Breakthrough in HIV Prevention: Twice-Yearly Injectable Lenacapavir Shows 100% Efficacy

Strategic Insights

— 1 min read

Lenacapavir, a twice-yearly injectable drug for HIV prevention, has shown remarkable results in its Phase 3 trial, demonstrating 100% efficacy in preventing HIV in cisgender women. The results were presented at the 25th International AIDS Conference (AIDS 2024) by Linda-Gail Bekker, CEO of the Desmond Tutu Health Foundation, and published in The New England Journal of Medicine. This breakthrough advancement in public health has significant implications for HIV prevention, particularly among women.

Key Takeaways:

  • The Phase 3, double-blind, active-controlled, multicenter, randomized trial of lenacapavir involved 5,345 HIV-negative, cisgender adolescent girls and young women aged 16-26 at 25 sites in South Africa and three sites in Uganda.
  • Lenacapavir demonstrated 100% efficacy in preventing HIV in cisgender women, with zero HIV infections observed in the treatment group compared to a background HIV incidence rate.
  • Gilead Sciences, the manufacturer of lenacapavir, expects results from its other pivotal trial, PURPOSE 2, in late 2024/early 2025, assessing twice-yearly lenacapavir for PrEP among various populations.
  • Winnie Byanyima, Executive Director of UNAIDS, highlighted the need for serious conversations around accessibility and pricing, with experts estimating the minimum price for mass production of a generic version at $40 a year.
  • Gilead Sciences is committed to HIV prevention and treatment and is working towards a strategy to enable broad, sustainable access globally, including swift access and regulatory approval in high-incidence, resource-limited countries.

Statistics:

  • 5,345 trial participants were involved in the Phase 3 trial of lenacapavir.
  • Zero HIV infections were observed among participants receiving lenacapavir treatment.
  • Lenacapavir is expected to be approved for PrEP in various populations by the end of 2024.
  • Estimated minimum price for mass production of a generic version of lenacapavir is $40 a year.
  • 100% efficacy was demonstrated in preventing HIV among cisgender women in the Phase 3 trial.

Sources:

  • "Data presented at AIDS 2024" (The New England Journal of Medicine, 2024)
  • [DELETED - as there are no quotes attached to the original text]
  • UNAIDS Executive Director Winnie Byanyima

Read more